Aktienanalyse zu Savara Inc (SVRA)SVRASavara Inc

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Savara Inc (SVRA) is currently priced at $4.45, which is significantly below the $12 price target set by JPMorgan, indicating potential upside. However, the stock has a very low RSI of 19.745, suggesting it is oversold, but the company has reported consistent losses with a forward P/E of 0.4076, indicating uncertainty in profitability. The main risk is the negative earnings trend, with EPS reported at -0.16, which reflects ongoing financial challenges.

5 analysts cover SVRA: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 10.17.